Nuance Communications Inc (NUAN) investors sentiment decreased to 0.8 in 2019 Q1. It’s down -0.38, from 1.18 in 2018Q4. The ratio has worsened, as 115 hedge funds started new or increased equity positions, while 144 sold and decreased stakes in Nuance Communications Inc. The hedge funds in our database now own: 261.61 million shares, up from 238.50 million shares in 2018Q4. Also, the number of hedge funds holding Nuance Communications Inc in top ten equity positions increased from 2 to 4 for an increase of 2. Sold All: 46 Reduced: 98 Increased: 82 New Position: 33.
The stock of FibroGen, Inc. (NASDAQ:FGEN) is a huge mover today! The stock increased 4.99% or $2.03 during the last trading session, reaching $42.71. About 223,267 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has declined 23.86% since June 17, 2018 and is downtrending. It has underperformed by 28.29% the S&P500. Some Historical FGEN News: 07/05/2018 – RESOURCE CAPITAL FUND Vl L.P. ANNOUNCES ACQUISITION OF UNITS IN LOS ANDES COPPER LTD; 09/05/2018 – FIBROGEN 1Q LOSS/SHR 50C, EST. LOSS/SHR 51C; 01/05/2018 – Imperas and Andes Extend Partnership, Delivering Models and Virtual Platforms for Andes RISC-V Cores with New AndeStar V5m; 31/05/2018 – ASTELLAS PHARMA INC – SAFETY PROFILE OF ROXADUSTAT WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUS STUDIES BOTH IN DIALYSIS AND NON-DIALYSIS PATIENTS; 18/04/2018 – The Andes Summit: More Than Ayahuasca – A Re-Validation of the Cultural Heritage of Ecuador’s Ancient Indigenous Wisdom; 09/05/2018 – FibroGen 1Q Rev $31.9M; 21/05/2018 – FIBROGEN: PAMREVLUMAB SLOWED IPF DISEASE PROGRESSION IN STUDY; 23/04/2018 – DJ FibroGen Inc, Inst Holders, 1Q 2018 (FGEN); 31/05/2018 – ASTELLAS PHARMA INC – FOURTH JAPAN PHASE 3 STUDY FOR ROXADUSTAT MET ITS PRIMARY ENDPOINT; 31/05/2018 – ASTELLAS PHARMA INC – ROXADUSTAT WAS WELL TOLERATED IN STUDYThe move comes after 9 months positive chart setup for the $3.68 billion company. It was reported on Jun, 17 by Barchart.com. We have $44.85 PT which if reached, will make NASDAQ:FGEN worth $184.15M more.
Among 5 analysts covering FibroGen (NASDAQ:FGEN), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. FibroGen had 8 analyst reports since December 19, 2018 according to SRatingsIntel. Mizuho maintained FibroGen, Inc. (NASDAQ:FGEN) rating on Thursday, February 28. Mizuho has “Buy” rating and $74 target. As per Monday, February 11, the company rating was maintained by Stifel Nicolaus. Citigroup upgraded the shares of FGEN in report on Wednesday, December 19 to “Buy” rating. The firm has “Buy” rating by Jefferies given on Thursday, February 28.
Analysts await FibroGen, Inc. (NASDAQ:FGEN) to report earnings on August, 6. They expect $-0.27 EPS, up 3.57% or $0.01 from last year’s $-0.28 per share. After $-0.53 actual EPS reported by FibroGen, Inc. for the previous quarter, Wall Street now forecasts -49.06% EPS growth.
More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Nasdaq.com which released: “November 15th Options Now Available For FibroGen (FGEN) – Nasdaq” on June 13, 2019, also Finance.Yahoo.com with their article: “Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register? – Yahoo Finance” published on June 10, 2019, Globenewswire.com published: “FibroGen Appoints Suzanne Blaug to Board of Directors – GlobeNewswire” on June 05, 2019. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Finance.Yahoo.com and their article: “Here’s What Hedge Funds Think About FibroGen Inc (FGEN) – Yahoo Finance” published on June 13, 2019 as well as Nasdaq.com‘s news article titled: “Sum Up The Parts: XBI Could Be Worth $125 – Nasdaq” with publication date: June 17, 2019.
FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $3.68 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
The stock decreased 0.74% or $0.12 during the last trading session, reaching $16.7. About 424,207 shares traded. Nuance Communications, Inc. (NUAN) has risen 36.76% since June 17, 2018 and is uptrending. It has outperformed by 32.33% the S&P500. Some Historical NUAN News: 22/03/2018 – NUANCE COMMUNICATIONS INC – MARK BENJAMIN CURRENTLY SERVES AS PRESIDENT AND CHIEF OPERATING OFFICER OF NCR CORP; 27/03/2018 – Neuberger Berman Calls on Resignation of Certain Nuance Board Members; 15/03/2018 – William Janeway Retires from Nuance Board of Directors; 07/03/2018 – Nuance and Epic Team to Deliver Array of Al-powered Healthcare Virtual Assistants; 09/05/2018 – NUANCE COMMUNICATIONS INC QTRLY GAAP REVENUE OF $514.2 MLN, UP 3% OVER PRIOR YEAR; 29/05/2018 – Nuance’s Conversational AI Platform Powers Revolutionary Mercedes Benz User Experience; 27/03/2018 – Neuberger Berman Sends Open Letter To Nuance Communications Board And Incoming CEO Mark Benjamin; 09/05/2018 – NUANCE SEES 2018 GROWTH 2% TO 4% ORGANIC GROWTH, SAW 3% TO 5%; 27/03/2018 – NEUBERGER BERMAN SENDS OPEN LETTER TO NUANCE COMMUNICATIONS; 27/03/2018 – Neuberger Berman Calls on Reform of Nuance’s Executive Pay Practices
Since January 1, 0001, it had 0 insider purchases, and 10 sales for $1.30 million activity.
Rgm Capital Llc holds 6.56% of its portfolio in Nuance Communications, Inc. for 5.71 million shares. 12Th Street Asset Management Company Llc owns 1.29 million shares or 5.78% of their US portfolio. Moreover, Park West Asset Management Llc has 2.6% invested in the company for 3.50 million shares. The New Jersey-based Mcrae Capital Management Inc has invested 2.41% in the stock. Kirr Marbach & Co Llc In, a Indiana-based fund reported 568,050 shares.
More notable recent Nuance Communications, Inc. (NASDAQ:NUAN) news were published by: Globenewswire.com which released: “Nuance Selects Industry Veteran Sanjay Dhawan to Lead Automotive Business – GlobeNewswire” on June 07, 2019, also Globenewswire.com with their article: “Nuance Automotive Powers Geely’s GKUI Smart Ecosystem – GlobeNewswire” published on May 23, 2019, Nasdaq.com published: “Nuance Drives Tangible Results for Healthcare Customers Through Cloud-based Clinical Documentation Excellence – Nasdaq” on May 21, 2019. More interesting news about Nuance Communications, Inc. (NASDAQ:NUAN) were released by: Globenewswire.com and their article: “Canadian-Based Northern Health Adopts Nuance AI-powered Dragon Medical One to Revolutionize Care Delivery Across British Columbia – GlobeNewswire” published on June 05, 2019 as well as Nasdaq.com‘s news article titled: “Amazon’s E-commerce Presence Expands With Prime Launch in UAE – Nasdaq” with publication date: June 13, 2019.
Nuance Communications, Inc. provides voice recognition and natural language understanding solutions worldwide. The company has market cap of $4.85 billion. It operates through four divisions: Healthcare, Mobile, Enterprise, and Imaging. It has a 101.86 P/E ratio. The Healthcare segment offers transcription solutions, which enables physicians to streamline clinical documentation with medical transcription platform; Dragon Medical, a dictation software that empowers physicians to accurately capture and document patient care in real-time on various devices; clinical document improvement and coding solutions to ensure patient health information is accurately documented, coded, and evaluated; and diagnostic solutions that allows radiologists to document, collaborate, and share medical images and reports.
Analysts await Nuance Communications, Inc. (NASDAQ:NUAN) to report earnings on August, 14. They expect $0.19 earnings per share, up 11.76% or $0.02 from last year’s $0.17 per share. NUAN’s profit will be $55.15M for 21.97 P/E if the $0.19 EPS becomes a reality. After $0.21 actual earnings per share reported by Nuance Communications, Inc. for the previous quarter, Wall Street now forecasts -9.52% negative EPS growth.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.